FDA Oncology Therapeutics Office Planned; Drug, Biologics Units To Be Merged
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency is understood to be finalizing a plan that would complete the integration of the oncology review teams as originally intended under the CDER/CBER consolidation. Oncology Drug Products Division Director Richard Pazdur, MD, and ODE VI Director Karen Weiss, MD, are potential candidates to head the merged cancer office.
You may also be interested in...
Dyax DX-88 Submission Likely Postponed For Additional Dosing Study
FDA seeks a subcutaneous dose-ranging study on the recombinant protein to treat hereditary angioedema.
Dyax DX-88 Submission Likely Postponed For Additional Dosing Study
FDA seeks a subcutaneous dose-ranging study on the recombinant protein to treat hereditary angioedema.
CDER Oncology Therapeutics Office To Contain Three Divisions
One of the divisions will focus on oncology imaging, Medical Policy Director Temple says. The "concept is settled" but the precise make-up of the other two divisions and a timeline for the implementation are not yet set, he says.